Patents by Inventor Brian H. White
Brian H. White has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11921788Abstract: A system level search module receives system level search user interface registration information for an application of the computing device. The registration information includes an indication of how the system level search module can launch the application. The registration information is added to a registration store, and the application is included as one of one or more applications that can be searched using the system level search user interface.Type: GrantFiled: November 29, 2022Date of Patent: March 5, 2024Assignee: Microsoft Technology Licensing, LLCInventors: Priya Vaidyanathan, Brian E. Uphoff, Brandon H. Paddock, Stephanie M. Monk, Dona Sarkar, Wentao Chen, Edward Boyle Averett, Manav Mishra, Derek S. Gebhard, Richard Jacob White, Yin Liu
-
Patent number: 11458206Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: GrantFiled: February 18, 2020Date of Patent: October 4, 2022Assignee: TVA (ABC), LLCInventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
-
Publication number: 20220288229Abstract: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: ApplicationFiled: May 23, 2022Publication date: September 15, 2022Inventors: Mark T. Bilodeau, Sudhakar Kadiyala, Rajesh R. Shinde, Brian H. White, Richard Wooster, Benoît Moreau
-
Publication number: 20220184217Abstract: Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: April 1, 2020Publication date: June 16, 2022Inventors: Brian H. White, Mark T. Bilodeau, Ashis K. Saha
-
Publication number: 20220096640Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: December 9, 2021Publication date: March 31, 2022Inventors: Benoît Moreau, Brian H. White, Mark T. Bilodeau, Mary Simcox, Kerry Whalen, Leila Alland, Richard Wooster, Rajesh R. Shinde
-
Patent number: 11241500Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: GrantFiled: December 14, 2017Date of Patent: February 8, 2022Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Benoît Moreau, Brian H. White, Mark T. Bilodeau, Mary Simcox, Kerry Whalen, Leila Alland, Richard Wooster, Rajesh R. Shinde
-
Publication number: 20220031853Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: September 13, 2019Publication date: February 3, 2022Inventors: Brian H. WHITE, Benoît MOREAU, Tyler CIPRIANI, Mark T. BILODEAU
-
Publication number: 20210145971Abstract: Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: April 3, 2019Publication date: May 20, 2021Inventors: Mark T. Bilodeau, Benoît Moreau, Sudhakar Kadiyala, Richard Wooster, Brian H. White
-
Publication number: 20210000966Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: December 14, 2018Publication date: January 7, 2021Inventors: Tyler Cipriani, Benoît Moreau, Mark T. Bilodeau, James M. Quinn, Richard Wooster, Amanda L. Cirello, Samantha Perino, Kerry Whalen, Sudhakar Kadiyala, Brian H. White
-
Publication number: 20200206356Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: ApplicationFiled: February 18, 2020Publication date: July 2, 2020Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
-
Publication number: 20200121808Abstract: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: ApplicationFiled: December 20, 2019Publication date: April 23, 2020Inventors: Mark T. Bilodeau, Sudhakar Kadiyala, Rajesh R. Shinde, Brian H. White, Richard Wooster, Benoît Moreau
-
Patent number: 10624967Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: GrantFiled: July 18, 2017Date of Patent: April 21, 2020Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
-
Publication number: 20200085960Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: December 14, 2017Publication date: March 19, 2020Inventors: Benoît Moreau, Brian H. White, Mark T. Bilodeau, Mary Simcox, Kerry Whalen, Leila Alland, Richard Wooster, Rajesh R. Shinde
-
Patent number: 10590135Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: GrantFiled: November 19, 2015Date of Patent: March 17, 2020Assignee: GLAXOSMITHKLINE LLCInventors: Charles A. Blum, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, William Henry Miller, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian H. White
-
Publication number: 20200078468Abstract: Conjugates of an active agent attached to a neurotensin receptor-binding targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.Type: ApplicationFiled: April 13, 2017Publication date: March 12, 2020Inventors: Mark T. Bilodeau, Mary Simcox, Brian H. White, Sudhakar Kadiyala, Richard Wooster
-
Publication number: 20200009262Abstract: Targeted constructs and pharmaceutical formulations thereof, comprising at least one conjugate of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via an optional internal linker moiety have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the targeted constructs and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: ApplicationFiled: May 12, 2017Publication date: January 9, 2020Inventors: Brian H. White, Benoît Moreau, Mark T. Bilodeau, Sudhakar Kadiyala
-
Patent number: 10322191Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: GrantFiled: July 18, 2017Date of Patent: June 18, 2019Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
-
Publication number: 20190125888Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as maytansinoid attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided.Type: ApplicationFiled: June 27, 2016Publication date: May 2, 2019Inventors: Brian H. White, Mark T. Bilodeau, Benoît Moreau, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Patrick Rosaire Bazinet, Rossitza G. Alargova, Craig A. Dunbar
-
Publication number: 20180044338Abstract: Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: August 4, 2017Publication date: February 15, 2018Inventors: Charles A. BLUM, Richard Dana CALDWELL, Rebecca CASAUBON, Jeremy S. DISCH, Ryan Michael FOX, Karsten KOPPETSCH, Pui Yee NG, Christopher OALMANN, Robert B. PERNI, Bruce G. SZCZEPANKIEWICZ, Brian H. WHITE
-
Patent number: 9879025Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.Type: GrantFiled: June 23, 2016Date of Patent: January 30, 2018Assignee: Infinity Pharmaceuticals, Inc.Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White